Document is current

Any future updates will be listed below

Effect of sodium–glucose transporter 2 inhibitor empagliflozin on proteinuria and kidney function progression in patients with non-diabetic glomerulonephritis: a pilot superiority randomized controlled trial

Crossref DOI link: https://doi.org/10.1007/s11255-023-03539-8

Published Online: 2023-03-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark